In Brief: U.S. Surgical
This article was originally published in The Gray Sheet
Executive SummaryU.S. Surgical: Receives 510(k) clearance for its Abbi system for minimally invasive breast biopsies. The firm claims the device can "minimize the amount of pain, disfigurement and scarring associated with open breast biopsy," cut procedure time and allow the use of local anesthesia in place of general anesthesia. The device consists of a stereotactic table made by ThermoTrex' Lorad unit and USSC's biopsy instrument ("The Gray Sheet" Feb. 5, p. 17)...
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.